Patents by Inventor Steven Almo

Steven Almo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FLT3 LIGAND BI-FUNCTIONAL MOLECULES FOR THROMBOPENIA AND ACUTE RADIATION SYNDROME
    Publication number: 20260055210
    Abstract: Provided herein are polypeptides, compositions, and methods for treating a cancer in an individual using a polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain. Also provided herein are nucleic acids encoding such polypeptides, expression vectors and cells comprising such nucleic acids, and methods of producing the polypeptides comprising a thrombopoietin domain and a Flt3 ligand domain. The administration of a fusion polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain to a subject may treat and reduce the symptoms of hematopoietic failure, including thrombopenia, and/or acute radiation syndrome.
    Type: Application
    Filed: August 23, 2023
    Publication date: February 26, 2026
    Inventors: Chandan GUHA, Steven ALMO, Phaneendra DUDDEMPUDI
  • THE IMMUNOMODULATORY LIGAND B7-1 MEDIATES SYNAPTIC REMODELING BY P75NTR
    Publication number: 20240201167
    Abstract: As described herein, binding of the B7-1 protein with the neuronal cell surface p75 neurotrophin receptor protein triggers loss of synaptic connections. Methods and compositions are also described for treatment of neurological diseases and conditions (including pain) and for identifying therapeutic agents useful for treatment of neurological diseases and conditions (including pain).
    Type: Application
    Filed: April 21, 2022
    Publication date: June 20, 2024
    Inventors: Barbara Hempstead, Francis Lee, Roshelle Smith, Victor Danelon, Steven Almo, Nicholas Morano, Sarah Garrett
  • Engineered PD-1 variants
    Patent number: 11905322
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD- L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: February 20, 2024
    Assignee: Albert Einstein College of Medicine
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
  • Engineered PD-1 variants
    Patent number: 11352413
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 7, 2022
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
  • ENGINEERED PD-1 VARIANTS
    Publication number: 20220098274
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Application
    Filed: May 3, 2021
    Publication date: March 31, 2022
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
  • ENGINEERED PD-1 VARIANTS
    Publication number: 20190127439
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 2, 2019
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei